Trimetazidine
Active pharmaceutical substance formulated in Jan Aushadhi generic products for Cardiac & Hypertension treatment.
🧴 Clinical Application
Take orally twice daily, one tablet in the morning and one in the evening with meals, swallowed with a glass of water. Modified-release tablets must be swallowed whole without chewing or crushing.
⚠️ Side Effects
Common: Dizziness, headache, abdominal pain, diarrhea, dyspepsia, nausea, vomiting, rash. Rare/Severe: Drug-induced Parkinsonian symptoms (tremors, akathisia, gait instability, rigidity), reversible upon discontinuation; restless legs syndrome, thrombocytopenia, and agranulocytosis.
🛡️ Safety Warnings
Contraindicated in Parkinson's disease, parkinsonian symptoms, tremors, and severe renal impairment (CrCl < 30 mL/min). Discontinue permanently if parkinsonian movement disorders occur. Not an abortive treatment for acute angina attacks.
Jan Aushadhi Products containing Trimetazidine
Found 2 generic formulation(s) containing this active ingredient.
Trimetazidine Hydrochloride Modified Release Tablets 35 mg
Trimetazidine Dihydrochloride is a myocardial metabolic anti-ischemic agent. It selectively inhibits the enzyme 3-ketoacyl-coenzyme A thiolase (3-KAT) in cardiac mitochondria, suppressing fatty acid beta-oxidation and shifting energy metabolism towards glucose oxidation. Glucose oxidation requires less oxygen consumption per unit of ATP produced, preserving myocardial cellular high-energy phosphate (ATP and phosphocreatine) levels during ischemia without altering heart rate, blood pressure, or coronary hemodynamics. Indicated as add-on therapy for the symptomatic treatment of adult patients with stable angina pectoris inadequately controlled by or intolerant to first-line therapies.
Trimetazidine Hydrochloride Controlled Release Capsules 60mg
Trimetazidine Dihydrochloride is a myocardial metabolic anti-ischemic agent. It selectively inhibits the enzyme 3-ketoacyl-coenzyme A thiolase (3-KAT) in cardiac mitochondria, suppressing fatty acid beta-oxidation and shifting energy metabolism towards glucose oxidation. Glucose oxidation requires less oxygen consumption per unit of ATP produced, preserving myocardial cellular high-energy phosphate (ATP and phosphocreatine) levels during ischemia without altering heart rate, blood pressure, or coronary hemodynamics. Indicated as add-on therapy for the symptomatic treatment of adult patients with stable angina pectoris inadequately controlled by or intolerant to first-line therapies.
Brand Equivalents & Price Comparison
Compare Jan Aushadhi generic prices against popular commercial brands for Trimetazidine.
| Generic Formulation | Pack Size | Jan Aushadhi Price | Commercial Brand Equivalents | Avg. Commercial Price | Savings |
|---|---|---|---|---|---|
| Trimetazidine Hydrochloride Modified Release Tablets 35 mg | 10's | ₹22.69 | FLAVEDON, TIMZID, TRINOL, CARVIDON, TRIVEDON | ₹156.91 | 86% Save |
| Trimetazidine Hydrochloride Controlled Release Capsules 60mg | 10's | ₹41.25 | CYTOGARD | ₹338.87 | 88% Save |
Frequently Asked Questions (FAQ)
Get answers to common queries about Trimetazidine generics.